ArticleBMC complementary medicine and therapies2025
Exploring the pharmacological action mechanism of chamomile essential oil on the treatment of breast cancer based on network pharmacology.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundChamomile essential oil (CEO) can be beneficial in cancer therapy. The aim of the current research is to explore the underlying mechanism of CEO for breast cancer treatment by network pharmacology approach and evaluate its anti-breast cancer capacity in vitro.
methodsWe extracted CEO from chamomile flowers and analyzed its chemical components by using GC-MS/MS. Network pharmacology method was employed to screen the active components, potential targets and possible mechanism of CEO for breast cancer treatment. The molecular docking was used to validate the results of network pharmacology. Cell viability, apoptosis and cell cycle assay were used to assess anti-breast cancer effect of CEO.
resultsIn network pharmacology analysis, we found the 12 effective components and 265 drug-disease common targets of CEO and among them, five active components and 19 targets were determined as the therapeutic targets of breast cancer. GO results demonstrated that the potential targets of CEO were primarily participated in positive regulation of MAPK cascade, distributed in membrane raft and the molecular functions were associated with protein serine-threonine-tyrosine kinase activity. KEGG pathway analysis suggested that the potential targets mainly involved in several signaling pathways such as PI3K-AKT, cAMP, neuroactive ligand-receptor interaction, MAPK and calcium signaling pathway. Molecular docking analysis revealed that LYN, LCK, VGFR, MAPK11, MAPK14, PTK2, JAK1, NR3C1 and ESR1 have shown higher affinity with three components from CEO and suggesting that these compounds might be the most effective ingredients against breast cancer. Besides, we found that CEO treatment suppressed cell proliferation by inducing cell cycle arrest in breast cancer cell lines.
conclusionsOur research suggest that CEO inhibit proliferation of breast cancer cell lines through modulating those multi-pathways and multi-targets. The present study not only indicate the therapeutic potential of CEO for breast cancer, but also provide valuable insight into its underlying mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.